Although there is a commercially available vaccine for Streptococcus equi subspecies equi licensed for the intranasal (IN) route of administration, some equine practitioners are administering this vaccine orally despite a lack of evidence for its efficacy by this route of administration. The purpose of this study was to compare systemic and local immune responses following IN or oral administration of the United States Department of Agriculture (USDA)-approved, live-attenuated S. equi subspecies equi vaccine (Pinnacle IN; Zoetis, Florham Park, NJ). Eight healthy horses with low S. equi M protein (SeM) titers (<1:1,600) were randomly assigned to an IN or oral two-vaccine series. Streptococcus equi M protein-specific serum immunoglobulins G (IgG) and A (IgA) and nasal secretion IgA were assessed using a commercially available ELISA (SeM ELISA, Equine Diagnostics Solutions, LLC, Lexington, KY) and a novel magnetic microsphere assay utilizing fluorescence. A general linear mixed models approach was used for statistical data analysis. As expected, IN vaccinates showed substantial increases in both serum SeM-specific IgG and IgA levels postvaccination (P ¼ .0006 and P ¼ .007, respectively). Oral vaccinates showed an increase in serum SeM-specific IgG postvaccination (P ¼ .0150), though only one third the magnitude of IN vaccinates. Oral vaccinates showed no evidence of change in SeM-specific IgA postvaccination (P ¼ .15). Results indicate that IN or oral vaccine administration resulted in increased serum SeM-specific IgG, though the magnitude of response differed, where there was a 10-fold increase for IN vaccinates and only a threefold increase for oral vaccinates.
Introduction
Streptococcus equi subspecies equi, a gram-positive, Lancefield group C streptococcus, is a highly contagious upper respiratory tract bacterial pathogen of horses. In susceptible populations, morbidity as a result of S. equi infection can reach 100% [1] . Due to its high contagiousness and its short-and long-term equine health implications, control of S. equi is of paramount importance to the equine industry. Infection with S. equi begins with entry into the mouth or nose, where the bacteria attaches to lingual, palatine, pharyngeal, and tubal tonsils [2] . Virulence factors including exposed surface proteins are involved in the attachment to and penetration of tonsils, followed by translocation to submandibular and retropharyngeal lymph nodes, and finally prevention of bacterial phagocytosis and destruction by neutrophils [2, 3] .
After recovery, approximately 75% of horses develop a strong immunity that persists for 5 years or more [2] . Surface proteins of S. equi, especially S. equi M protein (SeM), are highly immunogenic [4] , and measurement of SeM titers can help determine exposure (natural or vaccine), risk of adverse vaccination events, and diagnosis of complications of S. equi [2, 5] . Convalescent horses have been shown to develop a strong serum immunoglobulin Gb (IgGb) response to specific virulence factors of S. equi, in particular surface proteins (SeM), as well as strong SeM-specific mucosal immunoglobulin A (IgA) and IgGb responses [6, 7] . Optimal immunity likely relies on both systemic and mucosal immune responses [8] ; therefore, efficacious vaccines likely need to stimulate both for protection. A nonencapsulated, live-attenuated strain of S. equi [Pinnacle IN; Zoetis] has demonstrated efficacy against experimental challenge [9] . The intranasal (IN) administration of this attenuated vaccine mimics natural exposure to the pathogen and thus intends to stimulate a similar immune response. Adverse effects have been associated with this vaccine including abscess formation at remote sites, development of disease, or purpura hemorrhagica [10] . Another common problem associated with IN vaccination is removal of the attenuated strain by sneeze-mediated expulsion of nasal secretions. Due to these challenges, the zoonotic potential of S. equi [11] , and difficulty with the IN route of administration, some equine practitioners have adopted the oral route of vaccine administration for their equine patients. However, to date, there is no evidence to support that oral vaccination elicits a systemic immune response that could potentially confer host protection to pathogen challenge. Therefore, the primary objective of this study was to compare immune responses following oral administration of the attenuated vaccine strain relative to the licensed IN route of vaccination. We expected that the attenuated vaccine strain would come in contact with the pharyngeal tonsils following oral administration, as occurs with natural infection, thereby eliciting a measurable immune response. We monitored the systemic immune response by measuring serum SeM-specific IgG and IgA and the mucosal immune response by measuring nasal SeM-specific IgA in nasal secretions.
Materials and Methods

Subject Selection
Consistent with CONSORT vaccine trial guidelines, 13 healthy adult horses belonging to the Kansas State University College of Veterinary Medicine (KSU-CVM) teaching herd were examined for eligibility. Inclusion criteria for this study included horses younger than 25 years, determined to be healthy based on physical examination and baseline blood work (complete blood count and serum biochemistry) and that had a SeM titer <1:1,600 considered to be immunologically naïve with no history of previous vaccination or exposure/infection in at least the previous 24 months. The decision for selecting horses that had a SeM protein titer of <1:1,600 was based on the current standard of practice in accordance with the American College of Veterinary Internal Medicine S. equi consensus statement [2] .
For the duration of the experiment, horses received 2% of their body weight in prairie grass hay daily with water available free choice and concentrate supplementation as needed. No feeding changes were made as a component of this investigation; horses were fed and maintained following routine management of the teaching herd of horses at the KSU-CVM. Approval for this project was granted by the KSU Institutional Animal Care and Use Committee (IACUC #3285.1).
Study Design
Eleven out of 13 horses met inclusion criteria; and 8 out of 11 horses were selected to be included in the vaccine trial. Ages ranged from 5 to 23 years (mean ¼ 15 years) with body weights between 386 and 603 kg (mean ¼ 526 kg) in horses selected for investigation. Horses in the teaching herd were closed to contact with outside horses throughout the course of investigation. These horses were randomly assigned to receive either S. equi subsp. equi [Pinnacle IN; Zoetis] vaccination by the licensed IN or off-label oral route (n ¼ 4 horses each). Horses received initial vaccination on day 0 and a booster vaccination 3 weeks later on day 21, consistent with manufacturer guidelines. Horses were maintained in individual stalls for 3 days following vaccination treatment to reduce the potential for nose-to-nose contact with any other horses following vaccination. After being housed individually, horses were maintained in a stall with run environment.
In an added effort to ensure that there was no potential for natural, environmental exposure to S. equi subsp. equi, 3 out of the 11 horses that met inclusion criteria were used for analysis following IN saline administration. Timings of saline vaccination (2 doses, 21-day interval), sample collection, and sample processing were identical to vaccinate groups; however, due to CVM teaching horse availability, this surveillance experiment was performed at a separate time point 1 month following the vaccinates' experiment. During this time, there were no changes in teaching herd members or management. Analysis was performed separately for these three horses. This observational strategy was performed to provide some evidence that immunologic changes identified in vaccinated horses were specific to S. equi vaccination and not environmental exposure.
Sample Collection
Host immunity was assessed via systemic and local SeM-specific humoral immune responses measured prior to and after vaccination. Consistent with previous equine studies aimed at detection of humoral immune activation, a detectable level of antibody secretion present in nasal secretions was expected by 2 weeks following vaccination [12] . Based on known kinetics of primary and anamnestic host immune responses, a 4-week sampling interval following booster vaccination was selected to measure a serum immunoglobulin response [12, 13] . Therefore, at 2 and 4 weeks postbooster vaccination, nasal secretion and serum samples were obtained from each horse. Whole blood and serum were collected via jugular venipuncture. Samples were centrifuged (3,700 rpm for 10 minutes), aliquoted, and frozen at À80 C until analysis. Complete blood count and serum biochemistry samples were conducted at the clinical pathology laboratory at Kansas State University Veterinary Diagnostic Laboratory, and titers for serum IgG against SeM were quantified using an ELISA (SeM ELISA, Equine Diagnostics Solutions, LLC).
For collection of nasal secretion samples, horses were sedated with xylazine (AnaSed LA, Lloyd Laboratories Inc, Quezon City, Philippines) (0.5 mg/kg IV). This procedure was adapted from that described in horses [12] and cattle [14] to collect undiluted nasal secretions. A 4 Â 4 inch gauze square was prepared as the nasal secretion collection device by rolling it cylindrically and applying an adhesive strip for placement. The gauze was placed in the ventral nasal meatus of each horse, approximately 2 inches from the nostril opening and left in place for 20 minutes to allow for absorption of nasal secretions. The gauze square was then placed in a 50-mL conical tube. Once transported back to the laboratory, samples were spun down (2,000 rpm for 30 minutes) to concentrate secretions. The collected nasal secretions were aliquoted and frozen at À80 C until analysis.
Serum and nasal secretion samples were tested for SeM-specific IgA immunologic response to vaccination using magnetic microspheres (MagPlex microspheres, Luminex Corp., Austin, TX) in a modified sandwich ELISA method described in the following section.
Protein Coupling to Magnetic Microspheres
Carboxylated magnetic microspheres (MagPlex microspheres, Luminex Corp.) were coated with S. equi subsp. equi M protein via a carbodiimide reaction. The protocol was supplied by Luminex (Luminex MagPix, Luminex Corp., Austin, TX) laboratories [15] , as previously reported [16] , and used 5 mg of recombinant protein (kindly provided courtesy of Dr. John Timoney, Gluck Equine Research Center, University of Kentucky, Lexington, Kentucky) per 1 Â 10 6 microspheres (MagPlex microspheres, Luminex Corp.).
Quantitation of SeM Protein-Specific IgA
Dilutions used for both nasal secretion and serum samples were optimized at approximately 1:50 for SeM proteinspecific IgA detection. A working solution of SeM-coated microspheres (MagPlex microspheres, Luminex Corp.) was prepared in phosphate-buffered solution (PBS) to allow for 5,000 microspheres per well and 50 mL per well.
Serum or nasal secretion samples (1:50 dilutions in PBS) and microsphere solution were aliquoted into each of the appropriate wells of a 96-well plate (Greiner black plate, Greiner Bio-One North America Inc., Monroe, NC.) at 50 mL per well each. Each plate included a negative control of PBS solution to determine and compensate for background fluorescence. The plate was then sealed, protected from light, placed on a plate shaker, and allowed to incubate overnight at 4 C. The plate was then washed by placing it in the plate magnet (Magnetic Plate Separator, Luminex, Austin, TX) for 1 minute, decanting the supernatant, and resuspending the microspheres in each well with 100 mL PBS. The wash step was repeated twice. The microspheres were resuspended out of the plate magnet (Magnetic Plate Separator, Luminex) with 50 mL PBS per well. A secondary antibody solution was prepared to allow for 50 mL per well using goat anti-horse IgA (Goat anti-horse IgA, Bethyl Laboratories Inc., Montgomery, TX) at a concentration of 4 mg/mL. The plate was again sealed, protected from light, placed on a plate shaker, and allowed to incubate for 1 hour at room temperature. The plate was washed again three times. A detection antibody solution was prepared to allow for 50 mL per well using phycoerythrin-conjugated donkey anti-goat IgG (Thermo Fisher Scientific Inc., Rockford, IL) at a concentration of 4 mg/mL. The plate was incubated similarly for 30 minutes at room temperature. The plate was washed three times, and the microspheres were resuspended one final time with 100 mL of PBS per well.
The data acquisition protocol was analyzed using the Luminex MagPix (Luminex MagPix, Luminex Corp.) which excites fluorescence of phycoerythrin with a green (621 nm wavelength) light emitting diode and uses a chargecoupled device imager for mean fluorescence intensity (MFI) detection [15] . The MFI reported by the Luminex MagPix (Luminex MagPix, Luminex Corp.) was used as a measure of relative IgA quantification for each sample.
Statistical Analysis
Serum IgG SeM titers, as well as serum and nasal secretion SeM-specific IgA (measured in MFI), were expressed in the natural log-scale and fitted with a general linear mixed model. The linear predictor in the model included the fixed effects of treatment (oral vs. IN administration), time (prevaccination and postvaccination time point), and their two-way interaction. The random effect of horse nested within treatment was fitted to the model to identify the experimental unit for treatment and the unit of repeated observations over time.
Kenward Roger's procedure was used to estimate degrees of freedom and adjust estimated standard errors. Model assumptions were evaluated using externally studentized residuals and were considered to be reasonably met.
Statistical models were fitted using the GLIMMIX procedure of SAS (SAS Version 9.4, SAS Institute, Cary, NC) implemented using Newton-Raphson with ridging as the optimization technique. Estimated least square means and 95% confidence intervals are presented in the original scale of the data. Relevant pairwise comparisons were conducted using Bonferroni adjustment, as appropriate in each case to avoid inflation of type I error rate due to multiple comparisons.
Results
Immediately prior to the start of the study, there was no evidence for differences in serum IgG SeM titers (SeM ELISA, Equine Diagnostics Solutions, LLC) between horses assigned to receive IN or oral vaccination ( Fig. 1 ; P ¼ .83); neither was there any evidence for differences in relative SeM-specific IgA expression (in MFI) in serum or nasal secretions between groups (Figs. 2 and 3; P ¼ .93 and P ¼ .37, respectively). This is consistent with the expectation that horses recruited for this pilot study were previously unvaccinated and immunologically naïve to S. equi.
Two weeks following vaccination, an increase in serum
SeM-specific IgA (in MFI) was apparent for intranasally vaccinated horses only ( Fig. 2 ; P ¼ .0068); in turn, horses vaccinated through the oral route showed no evidence of changes in serum SeM-specific IgA ( Fig. 2 ; P ¼ .1504). Moreover, serum SeM-specific IgA levels by 2 weeks after vaccination were greater for horses vaccinated via the IN route than those vaccinated by the oral route ( Fig. 2 ; P ¼ .03). Regarding nasal secretion of SeM-specific IgA, neither group showed any evidence for changes from baseline to 2 weeks after the vaccine series ( Fig. 3 ; P ¼ .627).
By 4 weeks following completion of the 2-dose vaccination series, all vaccinated horses showed a significant increase in serum IgG SeM titer (SeM ELISA, Equine Diagnostics Solutions, LLC) regardless of route of vaccination ( Fig. 1; P ¼ .0132) ; however, the increase was substantially greater for horses vaccinated by the IN route (P ¼ .0006) compared with those vaccinated orally ( Fig. 1 ; P ¼ .0150). The magnitude of the increase in IgG SeM titer relative to baseline was estimated at approximately 10-fold for the intranasally vaccinated horses and at approximately threefold for the orally vaccinated horses.
Discussion
In the current report, horses were vaccinated with a USDA-approved, live-attenuated S. equi vaccine [Pinnacle IN; Zoetis] either via the licensed IN route or via the oral route. Results confirmed that horses vaccinated using the licensed IN route had a substantial increase in both serum SeM-specific IgG and IgA antibody levels postvaccination. Although a significant mean increase in IgG SeM titers was observed, it was noted that a considerable amount of variability was observed among horses, probably due to individual host immune responsiveness. Horses that were vaccinated using the oral route also showed an increase in the serum IgG SeM protein antibody level postvaccination, but not to the same magnitude as intranasally vaccinated horses. Orally vaccinated horses also did not show evidence for any response in serum SeM-specific IgA following vaccination. Horses vaccinated with IN saline did not show evidence of change in serum IgG SeM titer, serum SeM-specific IgA, or nasal secretion SeM-specific IgA ( Supplementary Figs. 1-3 , respectively) from prevaccination to postvaccination providing some evidence that the source of immunologic response in experimental horses was vaccine administration. The oral route of immunization is intriguing to stimulate mucosal-associated lymphoid tissue (MALT). Membranous microvillus (M) cells overlie lymphoid tissue of inductive sites such as the tonsils in the pharynx and Peyer's patches of the jejunum and ileum and are intimately associated with antigen-presenting cells [17] . Activation of M cells in the MALT causes homing of B cells to mucosal sites and production of specific IgA as well as systemic antibody production [17] . Nasal-and bronchial-associated lymphoid tissue may be stimulated by gut-associated lymphoid tissue antigen presentation as they are all part of MALT [18] . Oral administration of the nonencapsulated, live-attenuated S. equi vaccine [Pinnacle IN; Zoetis] may induce M cells overlying tonsils in the pharynx and subsequent mucosal antibody expression. A previous study evaluated oral administration of a killed S. equi vaccine compared to intraperitoneal administration to control horses after challenge [19] . Both vaccinated groups developed submandibular abscesses but were not as clinically ill (i.e., did not develop fever, anorexia, malaise) as control horses following challenge. Mucosal and systemic IgA and IgG were highest after challenge in the intraperitoneal vaccine group, but in the oral vaccine group, mucosal and systemic IgA was significantly increased compared to the control group [19] . Although the orally vaccinated horses in our study did show an increase in serum SeM-specific IgG titer at 4 weeks postbooster vaccination from baseline, some of the titers are still just a moderate positive (1:800-1:1,600) instead of a high positive (1:3,200-1:6,400) as would be expected following vaccination [2] . Sheoran et al [7] reported that serum titers peak at 5 weeks postexposure; therefore, the timing of sample collection at 4 weeks postbooster vaccination may not have detected the peak response from this group. The oral route of administration is appealing for several practical reasons, even though it may not provide consistently superior immune activation and protection.
Neither the IN nor the oral routes of vaccination elicited significant changes in nasal secretion SeM-specific IgA response in this study. These results contrast with those of Timoney [8] , who provided evidence that the attenuated IN S. equi vaccine induced both systemic and mucosal antibody responses. Changes in mucosal antibody responses may not have been identified in this study because of small changes in antibody response or timing of sample collection. Sheoran et al [7] reported that mucosal IgA in convalescent horses was first detected at 3 weeks postchallenge; however, in this study, nasal secretions were tested for IgA at 2 weeks postvaccination. Galan and Timoney [6] described mucosal IgA detection as early as 1 week following challenge when mucosal scrapings were tested at necropsy. Another vaccine study found peak mucosal IgA response at 16 days postinfluenza vaccination [12] . Therefore, a 2-week interval after vaccination was chosen in this study to measure mucosal IgA. The method of nasal secretion collection used in this study also may not have yielded as significant amounts of IgA as compared to other sampling methods. Sheoran et al [7] performed nasopharyngeal washings to successfully obtain diluted nasal washes for measurement of mucosal IgA after challenge. However, the adapted method of nasal secretion collection used in this study has been shown to collect undiluted nasal secretion samples previously [12, 14] .
In this investigation, no adverse effects to vaccination were found in any horses, consistent with other studies [9, Fort Dodge Animal Health licensing report TIA number: 22,740]. There has been work on the live-attenuated strain to remove the hasA and hasB genes making the microorganism acapsular and incapable of reversion to an encapsulated and more virulent form [9, 20] . In a study to assess the safety of the vaccine used in our study, it was determined that the vaccine was safe and efficacious in adult horses with low antibody titers but may cause clinical disease in young, naïve ponies [10] . Another study evaluated adverse behavioral responses to IN vaccine administration; horses did not show any adverse responses, whereas a few ponies did show substantial adverse reactions through avoidance behavior [21] .
A novel microsphere assay was used to measure immunologic response to S. equi vaccination. Potential advantages of the microsphere assay over the standard ELISA include smaller volumes of both protein and sample that are needed to perform the assay, as well as the potential to multiplex the assay to measure multiple analytes in the same sample [16] . Thus, this microsphere assay could also be modified for the quantitation of individual immunoglobulins (in ng/mL) in the sample, vs. serum titers, which may be useful for determining immunologic response to vaccination or immunologic status against S. equi with further development.
Conclusions
In conclusion, we identified responses in serum IgG SeM titer elicited by both IN and oral vaccination for S. equi using the USDA-approved, live-attenuated vaccine [Pinnacle IN; Zoetis]. However, the magnitude of the response was considerably greater following the IN route of vaccination. It is unknown whether the levels of serum IgG identified in orally vaccinated horses confer protection against S. equi. Further work is warranted to definitively determine the potential utility of oral vaccination in horses. Until that time, manufacturer guidelines for the USDA-approved, live-attenuated S. equi vaccine [Pinnacle IN; Zoetis] should be followed to ensure a maximal immune response. This work was supported by funding from Zoetis Inc., Florham Park, NJ (KSU-VHC G VCL 002872). K.H. is employed by Zoetis Inc.
